ABK-CDK-1 / Abbisko - LARVOL DELTA

Discovery of ABK-CDK-1, a selective and brain penetrant CDK4/2 inhibitor to overcome resistance of CDK4/6 inhibitors in breast cancer (AACR-NCI-EORTC 2025) - "However, the clinical benefit of first-generation CDK4/6 inhibitors—such as palbociclib, ribociclib, and abemaciclib—is limited by CDK6-mediated toxicity and the emergence of resistance driven in part by cyclin E/CDK2 activation. ABK-CDK-1, developed by Abbisko Therapeutics, is a novel selective and brain-penetrant CDK4/2 inhibitor with the potential to address limitations of current CDK4/6 inhibitors. Its promising efficacy, selectivity, and other properties support further preclinical advancement toward clinical development."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Eye Cancer • Hormone Receptor Breast Cancer • Oncology • Retinoblastoma • Solid Tumor • CDK1